

Asymmetric Synthesis of Propargylic Alcohols Using Bifunctional Glucose Dehydrogenases

Rohit Kumar, Simran Bhatia, Samantha J. Tambrini, and Guangde Jiang*

Table of Contents

	Page No.
General information	S2
Expression and Purification of Enzymes	S2-S4
Standard reaction conditions on a small scale	S4
Reactions of Ras-ADH	S5-S6
Determination of enantiomeric ratios of products	S6-S7
Gram-scale synthesis of product 2b using GDHs	S8
Deuterium labeling experiment	S9-S10
Proposed reaction mechanism	S10
General procedure for the chemical reduction of ketones	S11
General procedure for the biocatalytic reduction	S11
Characterization data	S11-S16
¹ H and ¹³ C Spectral data	S17-S28
HPLC spectra	S29-S37
References	S38

1. General Information

All catalytic reactions were performed in centrifuge tubes (1.5 mL or 50 mL) under rotation or in conical flasks (60 mL, 500 mL or 2 L) with shaking. Substrates **1a-j** and other reagents were purchased from commercial suppliers, such as Sigma-Aldrich, Oakwood Chemical, Enamine, Ambeed, Combi-Blocks, AA Blocks, and Cambridge Isotope Laboratories, and were used without further purification. The racemic compounds **2** were synthesized according to previously reported procedures using sodium borohydride (NaBH₄). Column chromatography was performed with ultrapure silica gel SiliaFlash® P60 from SILICYCLE Inc. (irregular shaped, 230-400 mesh). Nuclear magnetic resonance was performed on Bruker-Avance 400 MHz instrument. All ¹H NMR experiments are reported in units, parts per million (ppm) and were measured relative to the deuterated chloroform signal (7.26). All proton decoupled-¹³C NMR spectra are reported in ppm relative to deuterated chloroform (77.16). Chiral separation and enantiomeric purity check of the reaction products were determined with chiral columns on an Agilent 1260 Infinity II system using hexanes/isopropanol as the mobile phases. Molecular biology reagents were purchased from Fisher Scientific, Sigma-Aldrich, or New England Biolabs unless specified otherwise. *Escherichia coli* BL21 (DE3) was purchased from New England Biolab which was cultured in Luria-Bertani broth. The plasmids containing the DNA sequences of the enzymes were ordered from Twist Bioscience (San Francisco, CA).




Figure S1. Representative bioactive compounds containing a propargyl alcohol moiety.

2. Expression and Purification of Enzymes

The following procedures for protein expression and purification related to RasADH,¹ PTDH,² GDHs and their mutants were described elsewhere with slight modifications. The volume of 20 μ L stocked *E. Coli* BL21 cells harboring plasmid of the target enzyme was inoculated in 5 mL LB medium containing 100 μ g/mL kanamycin and grown overnight at 37°C. This overnight culture was utilized to inoculate 500 mL of TB medium containing 100 μ g/mL kanamycin, which was grown at 37 °C at 250 rpm until an OD₆₀₀ reached to 0.4-0.6, and subsequently induced with the addition of 0.2 mM isopropyl β -D-1-thiogalactopyranoside (IPTG). The induced culture was placed at 18 °C, 200 rpm, and cultured for 22 h

for protein expression. Following the above-mentioned expression procedures, the *E. Coli* BL21 cells containing the target enzyme were collected by centrifugation ($3,550 \times g$ for 15 min) and resuspended with sodium phosphate buffer (50 mM, pH 8.5). The mixture was lysed by sonication and clarified by centrifugation ($4 \text{ }^{\circ}\text{C}$, $3,550 \times g$ for 30 min). The protein was subsequently purified by affinity chromatography using HisPur™ Ni-NTA Resin (88222, Thermo Scientific™) according to the manufacturer's instructions. The purified protein was buffer exchanged against 50 mM sodium phosphate buffer, pH 8.5 using an Amicon Ultra concentration tube with 10 kDa cut-off. After that, the proteins were stored in 16% glycerol as 100-200 μL aliquots at $-80 \text{ }^{\circ}\text{C}$. Enzyme concentrations were determined spectrophotometrically using a NanoDrop instrument at 280 nm, based on calculated extinction coefficients from the amino acid sequence. The purified OsGDH protein was qualitatively analysed using 12% SDS-PAGE and gel was stained using Coomassie Brilliant Blue R-250. The PageRuler™ Prestained Protein Ladder (26616, Thermo Scientific™) was utilized to determine the molecular weights of key enzymes.




Figure S2: SDS-PAGE gels of key enzymes

Enzyme sequence

The enzyme sequences are underlined.

RasADH:

MGSSHHHHHSSGLVPRGSHMYRLLNKTA VITGGNSGIGLATAKRFVAEGAYVFIVGRRRKE
LEQAAAEIGRNVTAVKADVTKLEDLRLYAIVREQRGSIDVLFANSGAIEQKTL EEITPEHYDR
TFDVNVRGLIFTVQKALPLL RDGGSVILTSSVAGVLGLQAHD TYSAAKAAVRSLARTWTTELK
GRSIRVNAVSPGAIDTPIIENQVSTQEEADELRKFAAATPLGRVGRPEELAAAVLFLASDDSSY
VAGIELFVDGGLTQV

OsGDH:

MGSSHHHHHSSGLVPRGSHMSVSPYLLKGQKALVTGGSSGIGEAVARYLAKAGASVAINYH
SHPEEADKIVSDIQAGNGEAIQANVSKEDVKAMFAKMFQEFGTIDILVNNAGMQKDA AFL
DMTLEQWNLVINVNL TGQFLCAREAAKEFLRRGVQPHISSAAGKIICMSSVHEVIPWAGHVNY
AASKGGINMMMRMAQELAPHKIRVNSIAPGAIKTPINKSAWETPEAEAKLLTLIPAGR VGQV
EDIAKAAVWLASDDSDYVSGATL FVDGGMTLYPAFARGG

BsGDH:

MGSSHHHHHHSSGLVPRGSHMMYPDLKGKVVAITGAASGLGKAMAIRFGKEOAKVVINYYS
NKODPNEVKEEVIKAGGEAVVVOGDVTKEEDVKNIVOTAIKEFGTLDIMINNAGLENPVPSHE
MPLKDWDKVIKTNLTGAFLGSREAIKYFVENDIKGNVINMSSVHEVIPWPLFVHYAASKGGIK
LMTETLALEYAPKGIRVNNIGPGAINTPINAEKFADPKOKADVESMIPMGYIGEPEEIAAVAAW
LASKEASYVTGITLADGGMTQYPSFOAGRG

BsGDH_Q252K:

MGSSHHHHHHSSGLVPRGSHMMYPDLKGKVVAITGAASGLGKAMAIRFGKEOAKVVINYYS
NKODPNEVKEEVIKAGGEAVVVOGDVTKEEDVKNIVOTAIKEFGTLDIMINNAGLENPVPSHE
MPLKDWDKVIKTNLTGAFLGSREAIKYFVENDIKGNVINMSSVHEVIPWPLFVHYAASKGGIK
LMTETLALEYAPKGIRVNNIGPGAINTPINAEKFADPKOKADVESMIPMGYIGEPEEIAAVAAW
LASKEASYVTGITLADGGMTKYPSFOAGRG

BsGDH_L95V:

MGSSHHHHHHSSGLVPRGSHMMYPDLKGKVVAITGAASGLGKAMAIRFGKEOAKVVINYYS
NKODPNEVKEEVIKAGGEAVVVOGDVTKEEDVKNIVOTAIKEFGTLDIMINNAGVENPVPSHE
MPLKDWDKVIKTNLTGAFLGSREAIKYFVENDIKGNVINMSSVHEVIPWPLFVHYAASKGGIK
LMTETLALEYAPKGIRVNNIGPGAINTPINAEKFADPKOKADVESMIPMGYIGEPEEIAAVAAW
LASKEASYVTGITLADGGMTQYPSFOAGRG

3. Standard reaction conditions with **1a** as substrate in 0.0025 mmol scale

To a 1.5 mL centrifuge tube, NADP⁺ (1 mM), D-glucose (100 mM), and BsGDH or its mutant or OsGDH (1 mol%) in sodium phosphate buffer (50 mM, pH 7.0), and compound **1a** (10 μL of a 250 mM DMSO stock, 0.0025 mmol) were added sequentially. The total volume of the reaction mixture was 0.5 mL and the reaction was then allowed to rotate at 30 °C in a rotator (BS-RTTT-2, Stellar Scientific) for 24 hours. After the completion of reaction, 1,1,2,2-tetrachloroethane (10 μL of 250mM CDCl₃ stock, 0.0025 mmol) was added to the mixture. The mixture was extracted by adding 500 μL CDCl₃ and centrifuged with dried sodium sulphate. The contents were then transferred to a NMR tube and the product yields were then determined by ¹H NMR analysis.





Figure S3: Representative example of NMR yield calculation of product **2d**

4. Reactions of *Ras*-ADH with substrate **1a**



To a 1.5 mL centrifuge tube, NADP⁺ (1 mM), sodium phosphite (100 mM), *Ras*-ADH (1 mol%) and PTDH (1 mol%) in sodium phosphate buffer (50 mM, pH 7.0), and compound **1a** (10 μ L of a 250 mM DMSO stock, 0.0025 mmol) were added sequentially. The total volume of the reaction mixture was 0.5 mL and the reaction was then allowed to rotate at 30 $^{\circ}$ C in a rotator (BS-RTTT-2, Stellar Scientific) for 24 hours. After the completion of reaction, 1,1,2,2-tetrachloroethane (10 μ L of 250 mM CDCl₃ stock, 0.0025 mmol) was added to the mixture. The mixture was extracted by adding 500 μ L CDCl₃ and centrifuged with dried sodium sulfate. The contents were then transferred to a NMR tube and the product yields were then determined by ¹H NMR analysis. The reactions were done in duplicates.

After the determination of NMR yields, the compounds were transferred to HPLC vials fitted with inserts and were dried using nitrogen gas, after drying the mixture was redissolved in hexane:isopropanol (19:1). The enantiomeric ratio of the product was determined using an Agilent system equipped with a chiral HPLC column (Chiralcel[®] - OJ-H, 250 mm; *n*-hexane/*i*-PrOH = 70:30; 1 mL/min; detection at 245 nm). HPLC trace of racemic **2a**:



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.843	MM	0.2826	1.43220e4	844.55737	49.7941
2	12.860	MM	0.4116	1.44405e4	584.79803	50.2059

Reaction: *Ras*-ADH and PTDH as cofactor regeneration system




5. Determination of enantiomeric ratio


After the isolation, compounds were dissolved in hexane:isopropanol (19:1) and transferred to HPLC vials. The enantiomeric ratios were determined by the agilent 1260 Infinity II system with Chiralcel[®] - OD-H column.

5.1 Determination of stereochemistry of compounds

The stereochemistry of the compounds was confirmed using a previously known *Ras*-ADH which provides same products in (*S*)-configuration. The reaction of substrate **1b** was performed in the presence of *Ras*-ADH using BsGDH_K162M³ mutant for cofactor regeneration. The yield of product (*S*)-**2b** was confirmed using NMR (97%) and enantiomeric ratio was determined using chiral HPLC. HPLC separation (Chiralcel[®] - OD-H, *n*-hexane/*i*-PrOH = 90:10, 1 mL/min, detection at 210 nM).




HPLC trace of enantioenriched (*S*)-**2b** obtained from the catalytic reduction by *Ras*-ADH:




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.692	MM	0.1900	83.13416	7.29342	1.8275
2	6.374	MM	0.1821	4465.83105	408.80106	98.1725

5.2 Determining stereochemistry using commercially available (*R*)-**2b** ((*R*)-1-Phenyl-2-propyn-1-ol CAS No.: 61317-73-5


The HPLC Trace of (*R*)-**2b** (obtained from commercial source)



HPLC trace of enantioenriched (*S*)-**2b** obtained from the catalytic reduction by OsGDH:




6. Gram-scale synthesis of product **2b** using BsGDH_L95V




To a 2 L glass flask, NADP⁺ (1 mM), D-glucose (100 mM), and BsGDH_L95V wet cells (23.30 g, 38.83 g/L) in sodium phosphate buffer (50 mM, pH 7.0), DMSO and compound **1b** (1g dissolved in 30 mL DMSO) were added sequentially. The total volume of the reaction mixture was 600 mL, the reaction mixture was then kept in a shaker at 30°C at 220 rpm for 24 hours. Then the reaction mixture was diluted with 300 mL water which was extracted by 150 mL ethyl acetate. After two additional extractions, the combined organic layers were washed with brine (300 mL). The organic layer was dried over sodium sulfate and concentrated under vacuum to give the crude extract. The residue was then purified by column chromatography (90:10 hexane:ethyl acetate) on silica gel to give the target product, yield = 86% (870 mg).

HPLC chromatogram




7. Gram scale synthesis of product **2b** using OsGDH




To a 2 L glass bottle, NADP⁺ (1 mM), D-glucose (100 mM), and OsGDH wet cells (26.62 g, 44.36 g/L) in sodium phosphate buffer (50 mM, pH 7.0), DMSO and compound **1b** (1.3 g dissolved in 30 mL DMSO) were added sequentially. The total volume of the reaction mixture was 600 mL, the reaction mixture was then kept in a shaker at 30°C at 220 rpm for 24 hours. Then the reaction mixture was diluted with 300 mL water which was extracted by 150 mL ethyl acetate. After two additional extractions, the combined organic layers were washed with brine (300 mL). The organic layer was dried over sodium sulfate and concentrated under vacuum to give the crude extract. The residue was then purified by

column chromatography (90:10 hexane:ethyl acetate) on silica gel to give the target product, yield = 90% (1.194 g) *e.r.* = 98:2.

HPLC chromatogram



8.1 Deuterium labeling experiment with **1b** as substrate in 0.1 mmol scale



To a 50 mL falcon tube, NADP^+ (1 mM), D-glucose-1,2,3,4,5,6,6- d_7 (100 mM), and BsGDH_L95V (1 mol%) in sodium phosphate buffer (50 mM, pH 7.0), and compound **1a** (400 μL of a 250 mM DMSO stock, 0.1 mmol) were added sequentially. The total volume of the reaction mixture was 15 mL and the reaction was then allowed to rotate at 30 $^\circ\text{C}$ in a rotator for 24 hours. After the completion of reaction, the reaction mixture was transferred to separating funnel and was extracted by ethyl acetate (2×15 mL). The combined organic layers were dried over Na_2SO_4 and the contents were concentrated under reduced pressure. The residue was then purified by using preparative TLC to give the target product (**2b-d₁**), yield = 89% (11.8 mg). 91% Deuterium incorporation was observed at the α -position of the isolated product.




Figure S4: NMR spectra of **2b-d₁**

8.2 Proposed reaction mechanism




Figure S5: GDH catalytic mechanism

9. Procedure a: General procedure for the chemical reduction of ketones (1a-j):

The ketone (0.1 mmol) was dissolved in methanol (2 mL) and cooled to 0 °C with stirring. An excess of sodium borohydride (21.7 mg) was added, and the mixture was stirred for 15 min at 0 °C and then stirred additional four hours at room temperature. The reaction was quenched by dropwise addition of 1 M HCl until bubbling ceased. The volume of the mixture was reduced to 2 mL under reduced pressure, and ethyl acetate (10 mL) was added and the combined organic layers were washed by brine and then evaporated under reduced pressure to afford an oil. The resulting residue was purified by preparative TLC to afford corresponding alcohols.


10. Procedure b: General procedure for the biocatalytic reduction of ketones using BsGDH_L95V and OsGDH (1a-j):

To a 50 mL falcon tube, ketone (**1a-j**) (0.1 mmol in 400 μ L DMSO) along with NADP⁺ (1 mM) (400 μ L from 50 mM stock), D-glucose (100 mM) (2 mL from 1M stock), and BsGDH_L95V or OsGDH (1 mol%) was added to 50 mM NaPi buffer (10 mL) and total reaction volume was adjusted to 20 mL using sodium phosphate buffer (50 mM, pH 7.0). The reaction was then allowed to rotate at 30 °C in a rotator for 24 hours. After completion of the reaction, the reaction mixture was transferred to a separatory funnel and extracted with ethyl acetate (2 \times 15 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by preparative TLC to afford the target compound.

11. Characterization data

1,3-diphenylprop-2-yn-1-ol (Table 2, Entry 2a)


Following the general procedure a, 1,3-diphenylprop-2-yn-1-one (**1a**) (20.6 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, Yield = 87% (18 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 90:10, 1 mL/min, detection at 254 nM): = t_{r1} = 7.28 min, t_{r2} = 13.23 min.



Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 44% (9.2 mg), *e.r.* = 99.9:0.1 (*S*) using BsGDH_L95V and yield = 57% (11.9 mg) *e.r.* = 99.9:0.1 (*S*) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.63 (d, *J* = 7.6 Hz, 2H), 7.49 (d, *J* = 5.6 Hz, 2H), 7.42 (t, *J* = 7.2 Hz, 2H), 7.38 – 7.30 (m, 3H), 5.70 (s, 1H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 140.7, 131.9, 128.8, 128.8, 128.6, 128.4, 126.9, 122.5, 88.8, 86.8, 65.3. Spectroscopic data are in agreement with the reported values in the literature.⁴

1-phenylprop-2-yn-1-ol (Table 2, Entry 2b)


Following the general procedure for reduction, 1-phenylprop-2-yn-1-one (**1b**) (13 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as yellow oil, yield = 91% (12 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 90:10, 1 mL/min, detection at 210 nM): = t_{r1} = 4.73 min, t_{r2} = 6.29 min.



Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 89% (11.8 mg) *e.r.* = 1:99 (*S*) using BsGDH_L95V and yield = 92% (12.2 mg) *e.r.* = 4:96 (*S*) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.56 (d, *J* = 7.2 Hz, 2H), 7.42 – 7.33 (m, 3H), 5.48 (s, 1H), 2.68 (s, 1H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 140.1, 128.8, 128.7, 126.7, 83.6, 75.0, 64.6. Spectroscopic data are in agreement with the reported values in the literature.¹

1-(2-chlorophenyl)prop-2-yn-1-ol (Table 2, Entry 2c)


Following the general procedure for reduction, 1-(2-chlorophenyl)prop-2-yn-1-one (**1c**) (16.4 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as yellow oil, yield = 84% (14 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 90:10, 1 mL/min, detection at 220 nM): = t_{r1} = 4.38 min, t_{r2} = 4.93 min.



Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 93% (15.5 mg), *e.r.* = 1:99 (*S*) using BsGDH_L95V and yield = 96% (16 mg), *e.r.* = 1:99 (*S*) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.80 (d, *J* = 7.2 Hz, 1H), 7.41 (d, *J* = 7.6 Hz, 1H), 7.33 (p, *J* = 8.0, 7.2 Hz, 2H), 5.85 (s, 1H), 2.68 (s, 1H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 137.4, 132.8, 129.9, 129.8, 128.4, 127.4, 82.4, 75.0, 61.8. Spectroscopic data are in agreement with the reported values in the literature.⁵

1-(3-chlorophenyl)prop-2-yn-1-ol (Table 2, Entry 2d)

Following the general procedure for reduction, 1-(3-chlorophenyl)prop-2-yn-1-one (**1d**) (16.4 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as yellow oil, yield = 87% (14.4 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 90:10, 1 mL/min, detection at 220 nM): = t_{r1} = 4.50 min, t_{r2} = 4.88 min.




Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 91% (15.2 mg), *e.r.* = 1:99 (*S*) using BsGDH_L95V and yield = 92% (15.3 mg), *e.r.* = 1:99 (*S*) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.56 (s, 1H), 7.46 – 7.40 (m, 1H), 7.34 – 7.29 (m, 2H), 5.44 (s, 1H), 2.69 (s, 1H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 141.9,

134.6, 130.1, 128.8, 126.9, 124.9, 82.9, 75.5, 63.8. Spectroscopic data are in agreement with the reported values in the literature.⁶

1-(4-chlorophenyl)prop-2-yn-1-ol (Table 2, Entry 2e)


Following the general procedure for reduction, 1-(4-chlorophenyl)prop-2-yn-1-one (**1e**) (16.4 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as yellow oil, yield = 81% (13.4 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 98:02, 1 mL/min, detection at 220 nM): = t_{r1} = 11.16 min, t_{r2} = 11.74 min.



Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 95% (15.8 mg), 1:99 (*S*) using BsGDH_L95V and yield = 91% (15.1 mg), 6:94 (*S*) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.43 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 5.39 (s, 1H), 2.63 (s, 1H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 138.5, 134.5, 128.9, 128.1, 83.2, 75.3, 63.8. Spectroscopic data are in agreement with the reported values in the literature.¹

1-phenylbut-2-yn-1-ol (Table 2, Entry 2f)


Following the general procedure for reduction, 1-phenylbut-2-yn-1-one (**1f**) (14.4 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 88% (12.8 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 90:10, 1 mL/min, detection at 210 nM): = t_{r1} = 4.32 min, t_{r2} = 6.25 min.



Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 53% (7.8 mg), *e.r.* = 13:87 (*S*) using BsGDH_L95V and yield = 69% (10.1 mg), *e.r.* = 57:43 (*R*) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.54 (d, *J* = 7.6 Hz, 2H), 7.38 (t, *J* = 7.2 Hz, 2H), 7.35 – 7.30 (m, 1H), 5.44 (s, 1H), 1.92 (s, 3H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 141.3, 128.7, 128.4, 126.7, 83.3, 79.2, 64.9, 3.9. Spectroscopic data are in agreement with the reported values in the literature.¹

1-(4-bromophenyl)but-2-yn-1-ol (Table 2, Entry 2g)


Following the general procedure for reduction, 1-(4-bromophenyl)but-2-yn-1-one (**1g**) (22.3 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 87% (19.6 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 90:10, 1 mL/min, detection at 220 nM): = t_{r1} = 4.35 min, t_{r2} = 5.084 min.



Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 42% (9.5 mg), *e.r.* = 11:89 (*S*) using BsGDH_L95V and yield = 61% (13.8 mg), *e.r.* = 73:27 (*R*) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.49 (d, *J* = 8.0 Hz, 2H), 7.40 (d, *J* = 8.0 Hz, 2H), 5.38 (s, 1H), 1.90 (s, 3H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 140.3, 131.7, 128.4, 122.3, 83.7, 78.8, 64.3, 3.8. Spectroscopic data are in agreement with the reported values in the literature.⁷

4-phenylbut-3-yn-2-ol (Table 2, Entry 2h)


Purchased from Combi Blocks and used as such. HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 90:10, 1 mL/min, detection at 220 nM): = *t*_{r1} = 4.06 min, *t*_{r2} = 9.40 min.



Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 58% (8.3 mg) using BsGDH_L95V and yield = 93% (13.6 mg) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.46 – 7.39 (m, 2H), 7.30 (dd, *J* = 5.2, 2.0 Hz, 3H), 4.76 (q, *J* = 6.4 Hz, 1H), 1.56 (d, *J* = 6.4 Hz, 3H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 131.8, 128.5, 128.4, 122.7, 91.1, 84.1, 58.9, 24.5. Spectroscopic data are in agreement with the reported values in the literature.⁷

4-(4-chlorophenyl)but-3-yn-2-ol (Table 2, Entry 2i)

Following the general procedure for reduction, 4-(4-chlorophenyl)but-3-yn-2-one (**1i**) (17.8 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as light yellow oil, yield = 83% (15 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-PrOH 90:10, 1 mL/min, detection at 254 nM): = *t*_{r1} = 3.32 min, *t*_{r2} = 3.92 min.




Following the general procedure b, the title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 54% (9.8 mg), *e.r.* = 24:76 (*S*) using BsGDH_L95V and yield = 94% (17 mg), *e.r.* = 84:16 (*R*) using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.36 (d, *J* = 8.0 Hz, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), 4.76 (q, *J* = 6.4 Hz, 1H), 1.56 (d, *J* = 6.4 Hz, 3H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 134.4, 132.9, 128.6, 121.1, 91.9, 82.9, 58.8, 24.3. Spectroscopic data are in agreement with the reported values in the literature.⁸

4-(*o*-tolyl)but-3-yn-2-ol (Table 2, Entry 2j)

Following the general procedure for reduction, 4-(*o*-tolyl)but-3-yn-2-one (**1j**) (15.8 mg, 0.1 mmol), sodium borohydride (21.7 mg). Title compound was isolated by preparative TLC (30% EtOAc/*n*-hexane)

as light yellow oil, yield = 79% (12.6 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H), *n*-hexane/*i*-



PrOH 90:10, 1 mL/min, detection at 210 nM): = t_{r1} = 3.84 min, t_{r2} = 6.09 min.


Following the general procedure b, the title compound was isolated using preparative TLC (30% EtOAc/*n*-hexane) as colorless oil, yield = 77% (12.3 mg),

e.r. = 13:87 (*S*) using BsGDH_L95V and yield = 93% (14.9 mg) *e.r.* = 72:28 (*R*)

using OsGDH. ¹H NMR (400 MHz, CDCl₃, δ): 7.39 (d, *J* = 7.6 Hz, 1H), 7.24 – 7.18 (m, 2H), 7.13 (t, *J* = 6.8 Hz, 1H), 4.80 (q, *J* = 6.4 Hz, 1H), 2.43 (s, 3H), 1.58 (d, *J* = 6.4 Hz, 3H). ¹³C {¹H} NMR (100 MHz, CDCl₃, δ): 140.3, 132.1, 129.5, 128.5, 125.6, 122.4, 95.1, 82.9, 59.1, 24.7, 20.7. Spectroscopic data are in agreement with the reported values in the literature.⁹

1-(3-hydroxy-3-phenylprop-1-yn-1-yl)cyclohexan-1-ol (Scheme 3, Entry 3a)

To a stirred solution of the **2b** (2 mmol, 264 mg) in THF, was added ethylmagnesium bromide (Et-Mg-



Br) (1.0M in THF, 2.0 equivs.) at room temperature. The resulting solution was

reflux for 1 h at 80 °C. Then cyclohexanone (2 mmol, 1.0 equiv.) in THF (0.35M) was added slowly by syringe to the resulting solution at room

temperature and stirred for 3 h. The reaction mixture was quenched by addition

of saturated aqueous ammonium chloride (40 mL) and extracted with ethyl ether (2 x 40 mL). The

combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced

pressure. The crude material was purified by column chromatography. Isolated as light yellow oil, yield

= 79% (375 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H 250 mm then OJ-H 250 mm), *n*-

hexane/*i*-PrOH 80:20, 1 mL/min, detection at 210 nM): = t_{r1} = 8.94 min, t_{r2} = 9.93 min. ¹H NMR (400

MHz, CDCl₃, δ): 7.53 (d, *J* = 7.2 Hz, 2H), 7.39 – 7.29 (m, 3H), 5.48 (s, 1H), 2.83 (s, 1H), 2.53 (s, 1H),


1.95 – 1.91 (m, 2H), 1.72 – 1.65 (m, 2H), 1.623 – 1.48 (m, 5H), 1.25 (t, *J* = 7.2 Hz, 1H). ¹³C {¹H} NMR

(100 MHz, CDCl₃, δ): 140.8, 128.7, 128.4, 126.8, 90.5, 84.1, 68.8, 64.6, 39.9, 39.9, 25.2, 23.4.

Spectroscopic data are in agreement with the reported values in the literature.¹⁰

3,4-diiodo-2-phenyl-1-oxaspiro[4.5]dec-3-ene (Scheme 3, Entry 4a)

To a solution of **3a** (0.30 mmol, 70 mg) in wet CH₂Cl₂ (3.0 mL) was added 152.4 mg (0.6 mmol, 2equiv)



of I₂ at room temperature for 4 hours. After 4 h, the reaction mixture was diluted with ethyl ether (40 mL), washed with water, saturated brine, dried over Na₂SO₄

and evaporated under reduced pressure. The residue was purified by

chromatography on silica gel to afford corresponding product **4a**. Isolated as white solid, yield = 92%


(129 mg). HPLC separation (racemic) (Chiralcel[®] - OD-H 250 mm then OJ-H 250 mm), gradient method

n-hexane/*i*-PrOH 80:20, 0.5 mL/min from 0 min to 20 min, detection at 210 nM): = t_{r1} = 15.80 min, t_{r2} =

17.12 min. ^1H NMR (400 MHz, CDCl_3 , δ): 7.39 – 7.31 (m, 5H), 5.56 (s, 1H), 2.01 - 1.93 (m, 1H), 1.79 - 1.64 (m, 8H), 1.26 – 1.14 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , δ): 139.6, 128.8, 128.5, 128.0, 115.8, 107.3, 93.3, 92.1, 37.0, 34.3, 24.9, 22.3, 21.9. Spectroscopic data are in agreement with the reported values in the literature.¹⁰

1-phenylprop-2-yn-1-yl benzoate (Scheme 3, Entry 4a)

Phenyl propargyl alcohol, **2b** (264 mg, 2 mmol) was dissolved in CH_2Cl_2 (4 mL). DMAP (12 mg, 0.10 mmol), Et_3N (0.60 mL, 4.0 mmol) and benzoyl chloride (0.36 mL, 2.2 mmol) were sequentially added. The resulting mixture was stirred for 2 h. The solvent was evaporated and the residue was purified by column chromatography on silica gel affording the desired product **4a** (420 mg, 89%). HPLC separation (racemic)




(Chiralcel[®] - OD-H 250 mm then OJ-H 250 mm), *n*-hexane/*i*-PrOH 80:20, 1 mL/min, detection at 210 nM): = t_{r1} = 14.05 min, t_{r2} = 16.92 min. ^1H NMR (400 MHz, CDCl_3 , δ): 8.10 – 8.08 (m, 2H), 7.65 – 7.62 (m, 2H), 7.59 – 7.55 (m, 1H), 7.46 – 7.39 (m, 5H), 6.72 (d, J = 2.0 Hz, 1H), 2.71 (d, J = 2.4 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , δ): 165.5, 136.7, 133.5, 130.0, 129.7, 128.9, 128.5, 127.8, 80.4, 75.8, 65.9. Spectroscopic data are in agreement with the reported values in the literature.¹¹


13. ¹H and ¹³C Spectral data

1,3-diphenylprop-2-yn-1-ol (Table 3, Entry **2a**)

¹H NMR (400 MHz)




¹³C (100 MHz)




1-phenylprop-2-yn-1-ol (Table 3, Entry **2b**)

^1H NMR (400 MHz)




^{13}C (100 MHz)




1-(2-chlorophenyl)prop-2-yn-1-ol (Table 3, Entry 2c)

^1H NMR (400 MHz)




^{13}C (100 MHz)




1-(3-chlorophenyl)prop-2-yn-1-ol (Table 3, Entry 2d)

^1H NMR (400 MHz)




^{13}C (100 MHz)




1-phenylbut-2-yn-1-ol (Table 2, Entry 2f)

^1H NMR (400 MHz)




^{13}C (100 MHz)




1-(4-bromophenyl)but-2-yn-1-ol (Table 2, Entry 2g)

^1H NMR (400 MHz)




^{13}C (100 MHz)




4-phenylbut-3-yn-2-ol (Table 2, Entry 2h)

^1H NMR (400 MHz)




^{13}C (100 MHz)




4-(4-chlorophenyl)but-3-yn-2-ol (Table 2, Entry 2i)

^1H NMR (400 MHz)




^{13}C (100 MHz)




4-(*o*-tolyl)but-3-yn-2-ol (Table 2, Entry 2j)

^1H NMR (400 MHz)




^{13}C (100 MHz)




1-(3-hydroxy-3-phenylprop-1-yn-1-yl)cyclohexan-1-ol (Scheme 3, Entry 3a)

¹H NMR (400 MHz)




¹³C (100 MHz)




3,4-diiodo-2-phenyl-1-oxaspiro[4.5]dec-3-ene (Scheme 3, Entry 4a)

^1H NMR (400 MHz)




^{13}C (100 MHz)




1-phenylprop-2-yn-1-yl benzoate (Scheme 3, Entry 4b)

^1H NMR (400 MHz)




^{13}C (100 MHz)




14. HPLC spectra


HPLC trace of **rac-2a**:




HPLC trace of enantioenriched (*R*)-**2a** obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (*R*)-**2a** obtained from the catalytic reduction by OsGDH:




HPLC trace of **rac-2b**:




HPLC trace of enantioenriched (*S*)-**2b** obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (*S*)-**2b** obtained from the catalytic reduction by OsGDH:




HPLC trace of **rac-2c**:




HPLC trace of enantioenriched (*S*)-**2c** obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (*S*)-**2c** obtained from the catalytic reduction by OsGDH:




HPLC trace of **rac-2d**:




HPLC trace of enantioenriched (*S*)-**2d** obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (*S*)-**2d** obtained from the catalytic reduction by OsGDH:




HPLC trace of rac-2e:




HPLC trace of enantioenriched (S)-2e obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (S)-2e obtained from the catalytic reduction by OsGDH:




HPLC trace of rac-2f:




HPLC trace of enantioenriched (*R*)-**2f** obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (*S*)-**2f** obtained from the catalytic reduction by OsGDH:




HPLC trace of *rac*-**2g**:




HPLC trace of enantioenriched (*R*)-**2g** obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (*S*)-**2g** obtained from the catalytic reduction by OsGDH:




HPLC trace of *rac*-**2h**:




HPLC trace of enantioenriched (*R*)-**2h** obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (*S*)-**2h** obtained from the catalytic reduction by OsGDH:




HPLC trace of rac-2i:




HPLC trace of enantioenriched (R)-2i obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (S)-2i obtained from the catalytic reduction by OsGDH:




HPLC trace of rac-2j:




HPLC trace of enantioenriched (*R*)-**2j** obtained from the catalytic reduction by BsGDH_L95V:




HPLC trace of enantioenriched (*S*)-**2j** obtained from the catalytic reduction by OsGDH:




HPLC trace of **rac-3a**:




HPLC trace of enantioenriched **3a**:




HPLC trace of **rac-4a**:




HPLC trace of enantioenriched **4a**:



HPLC trace of **rac-4b**:



HPLC trace of enantioenriched **4b**:



12. References

1. S. González Granda, D. Méndez Sánchez, I. Lavandera and V. Gotor Fernández, *ChemCatChem*, 2020, **12**, 520-527.
2. T. W. Johannes, R. D. Woodyer and H. Zhao, *Biotechnol. Bioeng.*, 2007, **96**, 18-26.
3. G. Jiang, J. Lu, M. Zhou, W. Harrison and H. Zhao, *ACS Catal.*, 2024, **14**, 7074-7079.
4. C. Kamilya, S. S. Gorad and P. Ghorai, *Chem. Eur. J.*, 2024, **30**, e202303980.
5. G. Ieronimo, G. Palmisano, A. Maspero, A. Marzorati, L. Scapinello, N. Masciocchi, G. Cravotto, A. Barge, M. Simonetti and K. L. Ameta, *Org. Biomol. Chem.*, 2018, **16**, 6853-6859.
6. Y. Horino, J. Sakamoto, M. Murakami and M. Sugata, *Synlett*, 2020, **31**, 1323-1327.
7. Z. Zhang, J. T. Deng, J. Y. Feng, J. Y. Liang, X. T. Xu and J. B. Peng, *J. Org. Chem.*, 2023, **88**, 12054-12063.
8. X. Sang, F. Tong, Z. Zeng, M. Wu, B. Yuan, Z. Sun, X. Sheng, G. Qu, M. Alcalde and F. Hollmann, *Org. Lett.*, 2022, **24**, 4252-4257.
9. A. Falconnet, M. Magre, B. Maity, L. Cavallo and M. Rueping, *Angew. Chem. Int. Ed.*, 2019, **58**, 17567-17571.
10. K. G. Ji, H. T. Zhu, F. Yang, X. Z. Shu, S. C. Zhao, X. Y. Liu, A. Shaukat and Y. M. Liang, *Chem. Euro. J.*, 2010, **16**, 6151-6154.
11. X. Huang, T. de Haro and C. Nevado, *Chem. Euro. J.*, 2009, **15**, 5904-5908.